BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CMO Todd Berard sold 10,000 shares of the firm's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $15.67, for a total transaction of $156,700.00. Following the completion of the transaction, the chief marketing officer now directly owns 129,644 shares in the company, valued at approximately $2,031,521.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Todd Berard also recently made the following trade(s):
- On Wednesday, March 27th, Todd Berard sold 515 shares of BioLife Solutions stock. The shares were sold at an average price of $17.99, for a total transaction of $9,264.85.
- On Monday, March 11th, Todd Berard sold 401 shares of BioLife Solutions stock. The shares were sold at an average price of $17.42, for a total transaction of $6,985.42.
- On Wednesday, February 21st, Todd Berard sold 111 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,925.85.
- On Friday, January 19th, Todd Berard sold 1,232 shares of BioLife Solutions stock. The shares were sold at an average price of $16.76, for a total transaction of $20,648.32.
BioLife Solutions Trading Up 4.8 %
Biden replacement revealed?
From Paradigm Press | Ad
A former CIA insider just announced a disturbing prediction…
Biden will withdraw as the Democrat nominee on June 13.
See his shocking evidence in this new report
Shares of BLFS stock opened at $15.86 on Friday. The company has a 50 day moving average of $17.50 and a 200-day moving average of $15.32. The company has a quick ratio of 1.83, a current ratio of 2.86 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $24.50. The firm has a market cap of $718.46 million, a P/E ratio of -10.43 and a beta of 1.67.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The firm had revenue of $32.73 million during the quarter, compared to the consensus estimate of $32.70 million. Sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.6 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group started coverage on shares of BioLife Solutions in a research note on Thursday, April 4th. They issued a "buy" rating and a $22.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $23.40.
View Our Latest Analysis on BLFS
Institutional Trading of BioLife Solutions
Hedge funds have recently made changes to their positions in the stock. Huntington National Bank bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $1,697,000. Barclays PLC lifted its stake in BioLife Solutions by 205.3% in the third quarter. Barclays PLC now owns 56,968 shares of the medical equipment provider's stock worth $787,000 after purchasing an additional 38,311 shares during the last quarter. Millrace Asset Group Inc. bought a new stake in BioLife Solutions in the third quarter worth $676,000. Roubaix Capital LLC bought a new stake in BioLife Solutions in the third quarter worth $2,029,000. Finally, Everence Capital Management Inc. bought a new stake in BioLife Solutions in the third quarter worth $218,000. 93.24% of the stock is owned by institutional investors.
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
